( + )-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress through the activation of phenytoin-regulated σ1 sites

Hiroyuki Kamei, Tsutomu Kameyama, Toshitaka Nabeshima

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Mice exhibited a marked suppression of motility when they were replaced in the same environment in which they had previously received an electric footshock. This psychological stress-induced motor suppression, known as conditioned fear stress, was dose dependently attenuated by ( + )-N-allylnormetazocine (( + )-SKF-10,047) and by dextromethorphan, putative σ receptor agonists, but not by other σ receptor ligands, ( + )-pentazocine and 1,3-di-(2-tolyl)guanidine (DTG). Unlike ( + )-SKF-10,047 and dextromethorphan, the non-competitive NMDA receptor antagonists, phencyclidine and dizocilpine, attenuated the conditioned fear stress only at high doses that induced marked hypermotility in non-stressed mice. The effects of ( + )-SKF-10,047 and dextromethorphan, but not phencyclidine and dizocilpine, on the conditioned fear stress were antagonized by the σ receptor antagonists, NE-100 (N,N-dipropyl-2-[4-methoxy-3-(2-phenytethoxy)phenyl]-ethylamine monohydrochloride) and BMY-14802 (α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride). Interestingly, the effects of ( + )-SKF-10,047 and dextromethorphan on the stress response were enhanced by combination with phenytoin, an anticonvulsant drug, whereas those of ( + )-pentazocine, DTG, phencyclidine, and dizocilpine were not. These results suggest that activation of phenytoin-regulated type σ receptors, but not of phencyclidine receptors, is involved in the ameliorating effects of ( + )-SKF-10,047 and dextromethorphan on stress-induced motor suppression.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalEuropean Journal of Pharmacology
Volume299
Issue number1-3
DOIs
Publication statusPublished - 28-03-1996

Fingerprint

Dextromethorphan
Phenytoin
Fear
Phencyclidine
Dizocilpine Maleate
Pentazocine
Phencyclidine Receptors
N-Methyl-D-Aspartate Receptors
Psychological Stress
Anticonvulsants
Ligands

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

@article{ba5c5573152d497392ac9ac067105fad,
title = "( + )-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress through the activation of phenytoin-regulated σ1 sites",
abstract = "Mice exhibited a marked suppression of motility when they were replaced in the same environment in which they had previously received an electric footshock. This psychological stress-induced motor suppression, known as conditioned fear stress, was dose dependently attenuated by ( + )-N-allylnormetazocine (( + )-SKF-10,047) and by dextromethorphan, putative σ receptor agonists, but not by other σ receptor ligands, ( + )-pentazocine and 1,3-di-(2-tolyl)guanidine (DTG). Unlike ( + )-SKF-10,047 and dextromethorphan, the non-competitive NMDA receptor antagonists, phencyclidine and dizocilpine, attenuated the conditioned fear stress only at high doses that induced marked hypermotility in non-stressed mice. The effects of ( + )-SKF-10,047 and dextromethorphan, but not phencyclidine and dizocilpine, on the conditioned fear stress were antagonized by the σ receptor antagonists, NE-100 (N,N-dipropyl-2-[4-methoxy-3-(2-phenytethoxy)phenyl]-ethylamine monohydrochloride) and BMY-14802 (α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride). Interestingly, the effects of ( + )-SKF-10,047 and dextromethorphan on the stress response were enhanced by combination with phenytoin, an anticonvulsant drug, whereas those of ( + )-pentazocine, DTG, phencyclidine, and dizocilpine were not. These results suggest that activation of phenytoin-regulated type σ receptors, but not of phencyclidine receptors, is involved in the ameliorating effects of ( + )-SKF-10,047 and dextromethorphan on stress-induced motor suppression.",
author = "Hiroyuki Kamei and Tsutomu Kameyama and Toshitaka Nabeshima",
year = "1996",
month = "3",
day = "28",
doi = "10.1016/0014-2999(95)00830-6",
language = "English",
volume = "299",
pages = "21--28",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

( + )-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress through the activation of phenytoin-regulated σ1 sites. / Kamei, Hiroyuki; Kameyama, Tsutomu; Nabeshima, Toshitaka.

In: European Journal of Pharmacology, Vol. 299, No. 1-3, 28.03.1996, p. 21-28.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ( + )-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress through the activation of phenytoin-regulated σ1 sites

AU - Kamei, Hiroyuki

AU - Kameyama, Tsutomu

AU - Nabeshima, Toshitaka

PY - 1996/3/28

Y1 - 1996/3/28

N2 - Mice exhibited a marked suppression of motility when they were replaced in the same environment in which they had previously received an electric footshock. This psychological stress-induced motor suppression, known as conditioned fear stress, was dose dependently attenuated by ( + )-N-allylnormetazocine (( + )-SKF-10,047) and by dextromethorphan, putative σ receptor agonists, but not by other σ receptor ligands, ( + )-pentazocine and 1,3-di-(2-tolyl)guanidine (DTG). Unlike ( + )-SKF-10,047 and dextromethorphan, the non-competitive NMDA receptor antagonists, phencyclidine and dizocilpine, attenuated the conditioned fear stress only at high doses that induced marked hypermotility in non-stressed mice. The effects of ( + )-SKF-10,047 and dextromethorphan, but not phencyclidine and dizocilpine, on the conditioned fear stress were antagonized by the σ receptor antagonists, NE-100 (N,N-dipropyl-2-[4-methoxy-3-(2-phenytethoxy)phenyl]-ethylamine monohydrochloride) and BMY-14802 (α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride). Interestingly, the effects of ( + )-SKF-10,047 and dextromethorphan on the stress response were enhanced by combination with phenytoin, an anticonvulsant drug, whereas those of ( + )-pentazocine, DTG, phencyclidine, and dizocilpine were not. These results suggest that activation of phenytoin-regulated type σ receptors, but not of phencyclidine receptors, is involved in the ameliorating effects of ( + )-SKF-10,047 and dextromethorphan on stress-induced motor suppression.

AB - Mice exhibited a marked suppression of motility when they were replaced in the same environment in which they had previously received an electric footshock. This psychological stress-induced motor suppression, known as conditioned fear stress, was dose dependently attenuated by ( + )-N-allylnormetazocine (( + )-SKF-10,047) and by dextromethorphan, putative σ receptor agonists, but not by other σ receptor ligands, ( + )-pentazocine and 1,3-di-(2-tolyl)guanidine (DTG). Unlike ( + )-SKF-10,047 and dextromethorphan, the non-competitive NMDA receptor antagonists, phencyclidine and dizocilpine, attenuated the conditioned fear stress only at high doses that induced marked hypermotility in non-stressed mice. The effects of ( + )-SKF-10,047 and dextromethorphan, but not phencyclidine and dizocilpine, on the conditioned fear stress were antagonized by the σ receptor antagonists, NE-100 (N,N-dipropyl-2-[4-methoxy-3-(2-phenytethoxy)phenyl]-ethylamine monohydrochloride) and BMY-14802 (α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol hydrochloride). Interestingly, the effects of ( + )-SKF-10,047 and dextromethorphan on the stress response were enhanced by combination with phenytoin, an anticonvulsant drug, whereas those of ( + )-pentazocine, DTG, phencyclidine, and dizocilpine were not. These results suggest that activation of phenytoin-regulated type σ receptors, but not of phencyclidine receptors, is involved in the ameliorating effects of ( + )-SKF-10,047 and dextromethorphan on stress-induced motor suppression.

UR - http://www.scopus.com/inward/record.url?scp=0029867876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029867876&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(95)00830-6

DO - 10.1016/0014-2999(95)00830-6

M3 - Article

C2 - 8901003

AN - SCOPUS:0029867876

VL - 299

SP - 21

EP - 28

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -